Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study

Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study

Background. In an era of breakthroughs in cancer immunotherapy, CheckMate 067 studies declared the combination of PD-1 and CTLA-4 inhibitors a new standard of care for patients with metastatic melanoma (MM). A significant limitation of the widespread use of the combination of ipilimumab and nivoluma...

Full description

Bibliographic Details
Main Authors: Igor V. Samoylenko, Lev V. Demidov, Fedor V. Moiseenko, Mikhail V. Dvorkin, Svetlana A. Demidova, Svetlana A. Protsenko, Daniil L. Stroyakovskiy, Vadim V. Kozlov, Svetlana V. Odintsova, Dmitry V. Kirtbaya, Denis A. Tantsyrev, Anastasia S. Mochalova, Rashida V. Orlova, Guzel Z. Mukhametshina, Natalia V. Fadeeva, Evgeny A. Fomin, Yana S. Chapko, Anna V. Tarasova, Nikolay B. Ermakov, Alexander K. Shemerovskiy, Vera A. Vaschenko, Valery M. Chistyakov, Arina V. Zinkina-Orikhan, Yulia N. Lin'kova, Fedor B. Kryukov, Irina V. Sorokina, Anna A. Siliutina
Format: Article
Language:Russian
Published: IP Habib O.N. 2023-12-01
Series:Современная онкология
Subjects:
nurulimab+prolgolimumab combination
nurulimab
prolgolimumab
unresectable melanoma
metastatic melanoma
oberton study
miraculum study
immunotherapy
combination immunotherapy
bcd-217-2 octava
anti-ctla-4
anti-pd-1
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/624195/139984

Internet

https://modernonco.orscience.ru/1815-1434/article/viewFile/624195/139984

Similar Items